Helen Sklyarova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Helen Sklyarova has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Eugen Sklyarov
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
4 shared publications - Lesya Kobylinska
Department of Biochemistry, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
3 shared publications - Nataliia K. Pokrovska
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
3 shared publications - Iryna Fomenko
Department of Biochemistry, DNT “Danylo Halytsky Lviv National Medical University”, Ukraine
2 shared publications - Nataliia Denysenko
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
2 shared publications - Sandor George Vari
International Research and Innovation in Medicine Program, Cedars–Sinai Medical Center, Los Angeles, CA 90048, USA
2 shared publications
Latest Publications
- Open Access
- 30 September 2026
- Published by Ukrainian Military Medical Academy in Ukrainian Journal of Military Medicine
- Vol. 7 (3) , 131-137
Connective tissue growth factor levels in military personnel following mine-blast trauma
The aim. To perform a comparative assessment of serum CTGF levels between non-injured military personnel and those with consequences of MBT. Materials and Methods. The study included 89 participants examined at the First Territorial Medical Union in Lviv. Group 1 included 39 non-injured military personel, Group 2 - 40 military personel with consequences of MBT. The control group consisted of 10 apparently healthy individuals. All participants underwent complete blood count, biochemical blood analysis, coagulation profile, lipid profile, and transthoracic echocardiography. Serum CTGF concentrations were measured using the Finetest ELISA Kit. Results. Systolic BP was significantly higher in Group 2 compared with Group 1 (p=0,037). Serum CTGF level was significantly elevated in Group 2 compared to Group 1 and the control group (Group 2: 1495,7 (1169,3; 1808.6) pg/mL; Group 1: 776,7 (570,4; 914,7) pg/mL, p = 0,023; control group: 712,4 (625,8; 816,3) pg/mL, p = 0,002). In Group 1, significant correlations were found between CTGF levels and IL-33 (r=0,509; p=0,001), IL1RL1 (r=0,406; p=0,010), TGF-β (r=0,424; p=0,007), total bilirubin (r=0,759; p=0,001), LDL-C (r=0,534; p=0,003), and glucose (r=0,391; p=0,039). In Group 2, CTGF levels correlated significantly with IL-33 (r=0,331; p=0,037), heparan sulfate (r=0,328; p=0,039), activated partial thromboplastin time (r=0,752; p=0,032), total fibrinogen (r=0,490; p=0,028), and left atrial dimension (r=0,313; p=0,049). Echocardiographic assessment revealed significantly greater right ventricular size (p=0,011), interventricular septal thickness (p=0,048), left ventricular posterior wall thickness (p=0,017), and left ventricular myocardial mass (p=0,009) in Group 2. Type I diastolic dysfunction was diagnosed significantly more frequently in Group 2 (Group 1: 17,9%; Group 2: 40,0%; p = 0,031). Conclusions. CTGF may be considered a marker of myocardial remodeling under the influence of elevated BP and the development of LV diastolic dysfunction. CTGF level was significantly higher in military personnel with consequences of combat trauma (p=0,023). In patients of this group, a statistically higher systolic BP was diagnosed (p = 0,037), along with a higher prevalence of concentric LV remodeling (p = 0,009), and type I diastolic dysfunction (p = 0,031). Significant positive correlations between CTGF and IL-33, IL1RL1, TGF-β, and heparan sulfate indicate the involvement of this marker in the inflammatory process and the development of endothelial dysfunction.
- 30 September 2026
- Published by Ukrainian Military Medical Academy in Ukrainian Journal of Military Medicine
- Vol. 7 (3) , 131-137
Open AccessConnective tissue growth factor levels in military personnel following mine-blast trauma
The aim. To perform a comparative assessment of serum CTGF levels between non-injured military personnel and those with consequences of MBT. Materials and Methods. The study included 89 participants examined at the First Territorial Medical Union in Lviv. Group 1 included 39 non-injured military personel, Group 2 - 40 military personel with consequences of MBT. The control group consisted of 10 apparently healthy individuals. All participants underwent complete blood count, biochemical blood analysis, coagulation profile, lipid profile, and transthoracic echocardiography. Serum CTGF concentrations were measured using the Finetest ELISA Kit. Results. Systolic BP was significantly higher in Group 2 compared with Group 1 (p=0,037). Serum CTGF level was significantly elevated in Group 2 compared to Group 1 and the control group (Group 2: 1495,7 (1169,3; 1808.6) pg/mL; Group 1: 776,7 (570,4; 914,7) pg/mL, p = 0,023; control group: 712,4 (625,8; 816,3) pg/mL, p = 0,002). In Group 1, significant correlations were found between CTGF levels and IL-33 (r=0,509; p=0,001), IL1RL1 (r=0,406; p=0,010), TGF-β (r=0,424; p=0,007), total bilirubin (r=0,759; p=0,001), LDL-C (r=0,534; p=0,003), and glucose (r=0,391; p=0,039). In Group 2, CTGF levels correlated significantly with IL-33 (r=0,331; p=0,037), heparan sulfate (r=0,328; p=0,039), activated partial thromboplastin time (r=0,752; p=0,032), total fibrinogen (r=0,490; p=0,028), and left atrial dimension (r=0,313; p=0,049). Echocardiographic assessment revealed significantly greater right ventricular size (p=0,011), interventricular septal thickness (p=0,048), left ventricular posterior wall thickness (p=0,017), and left ventricular myocardial mass (p=0,009) in Group 2. Type I diastolic dysfunction was diagnosed significantly more frequently in Group 2 (Group 1: 17,9%; Group 2: 40,0%; p = 0,031). Conclusions. CTGF may be considered a marker of myocardial remodeling under the influence of elevated BP and the development of LV diastolic dysfunction. CTGF level was significantly higher in military personnel with consequences of combat trauma (p=0,023). In patients of this group, a statistically higher systolic BP was diagnosed (p = 0,037), along with a higher prevalence of concentric LV remodeling (p = 0,009), and type I diastolic dysfunction (p = 0,031). Significant positive correlations between CTGF and IL-33, IL1RL1, TGF-β, and heparan sulfate indicate the involvement of this marker in the inflammatory process and the development of endothelial dysfunction.
- Open Access
- 20 June 2025
- Published by Danylo Halytskyi Lviv National Medical University in Proceeding of the Shevchenko Scientific Society. Medical Sciences
- Vol. 77 (1)
CHANGES IN THE LEVELS OF ST2 AND GALECTIN-3 IN THE BLOOD SERUM OF PATIENTS WITH ARTERIAL HYPERTENSION
Introduction. Soluble suppression of tumorigenicity 2 (sST2) and galectin-3 are considered markers of myocardial hypertrophy and fibrosis. Changes in their concentrations are observed in cardiovascular diseases, including arterial hypertension. The aim. To determine threshold values of hypertrophy and fibrosis biomarkers, namely sST2 and galectin-3, in patients with arterial hypertension. Materials and methods. A prospective study was conducted on 82 patients with arterial hypertension (AH). Patients were stratified into two groups based on left ventricular mass index (LVMI) values: Group 1 with left ventricular hypertrophy (LVMI > 115 g/m² for men and 90 g/m² for women, n=33) and Group 2 with normal LVMI values (n=27). Results. Patients with left ventricular hypertrophy exhibited significantly elevated sST2 and galectin-3 levels. Direct correlations were observed between LVMI and sST2 values (r=0.6397; p=0.000) and galectin-3 (r=0.5113; p=0.001). Both biomarkers correlated with various cardiac parameters, including interventricular septal thickness at end-diastole, left atrial diameter, left ventricular end-diastolic diameter, and posterior wall thickness at end-diastole (specifically with sST2). With a selected sST2 value of 17.0 ng/ml, the diagnostic method demonstrated 88.33% accuracy, 92.59% specificity, 93.3% positive predictive value, and 83.33% negative predictive value for hypertrophy. At the chosen galectin-3 level of 29.0 ng/ml, the proposed method achieved 72.22% accuracy, 73.68% sensitivity, 70.59% specificity, 73.68% positive predictive value, and 70.59% negative predictive value. In conclusion, measuring sST2 and galectin-3 biomarkers facilitates the evaluation of left ventricular hypertrophy, serving as an additional tool in assessing cardiac dysfunction and indicating diverse developmental pathways.
- 20 June 2025
- Published by Danylo Halytskyi Lviv National Medical University in Proceeding of the Shevchenko Scientific Society. Medical Sciences
- Vol. 77 (1)
Open AccessCHANGES IN THE LEVELS OF ST2 AND GALECTIN-3 IN THE BLOOD SERUM OF PATIENTS WITH ARTERIAL HYPERTENSION
Introduction. Soluble suppression of tumorigenicity 2 (sST2) and galectin-3 are considered markers of myocardial hypertrophy and fibrosis. Changes in their concentrations are observed in cardiovascular diseases, including arterial hypertension. The aim. To determine threshold values of hypertrophy and fibrosis biomarkers, namely sST2 and galectin-3, in patients with arterial hypertension. Materials and methods. A prospective study was conducted on 82 patients with arterial hypertension (AH). Patients were stratified into two groups based on left ventricular mass index (LVMI) values: Group 1 with left ventricular hypertrophy (LVMI > 115 g/m² for men and 90 g/m² for women, n=33) and Group 2 with normal LVMI values (n=27). Results. Patients with left ventricular hypertrophy exhibited significantly elevated sST2 and galectin-3 levels. Direct correlations were observed between LVMI and sST2 values (r=0.6397; p=0.000) and galectin-3 (r=0.5113; p=0.001). Both biomarkers correlated with various cardiac parameters, including interventricular septal thickness at end-diastole, left atrial diameter, left ventricular end-diastolic diameter, and posterior wall thickness at end-diastole (specifically with sST2). With a selected sST2 value of 17.0 ng/ml, the diagnostic method demonstrated 88.33% accuracy, 92.59% specificity, 93.3% positive predictive value, and 83.33% negative predictive value for hypertrophy. At the chosen galectin-3 level of 29.0 ng/ml, the proposed method achieved 72.22% accuracy, 73.68% sensitivity, 70.59% specificity, 73.68% positive predictive value, and 70.59% negative predictive value. In conclusion, measuring sST2 and galectin-3 biomarkers facilitates the evaluation of left ventricular hypertrophy, serving as an additional tool in assessing cardiac dysfunction and indicating diverse developmental pathways.
- Open Access
- 30 September 2024
- Published by Bogomolets National Medical University in Medical Science of Ukraine (MSU)
- Vol. 20 (3) , 24-33
THE ROLE OF ADIPONECTIN, VISFATIN AND IRISIN IN THE PATHOGENESIS AND TREATMENT OF ARTERIAL HYPERTENSION
Background. The pathogenesis of arterial hypertension is not fully understood, although the main mechanisms of blood pressure regulation are generally outlined. An important role in the pathogenesis of hypertension, in addition to the well-known factors, is played by excessive expression of pro-inflammatory cytokines, which are produced by adipose tissue. Aim: to determine the role of adiponectin, visfatin and irisin in the pathogenesis and treatment of arterial hypertension. Materials and methods. 70 patients with arterial hypertension were examined in a randomized manner. Patients were divided into two groups: group 1 - 33 patients with controlled blood pressure and group 2 - 37 people with elevated blood pressure. All study participants underwent a thorough collection of disease and life anamnesis, a general physical examination with measurement of blood pressure (BP), anthropometric measurements with calculation of body mass index (BMI), complete blood count, coagulation test, blood chemistry test, as well as, enzyme-linked immunosorbent assay to determine the level of adiponectin, visfatin, irisin in blood serum and lymphocytes. An echocardiographic examination (EchoCG) was additionally performed. Results. Patients of the first group with normal blood pressure had significantly higher levels of adiponectin (p ˂ 0.01) and irisin (p ˂ 0.05) in blood serum, as well as significantly lower levels of visfatin in blood serum (p ˂ 0.05) compared to the patients of the second group. On the other hand, in lymphocytes, no significant difference was found between the indicators of adiponectin and visfatin between patients of the first and second groups. A positive correlation was found between the level of visfatin in lymphocytes and age (r=0.308; p ˂0.05), fibrinogen (r=0.472; p ˂0.01) and INR (r=0.551; p ˂0.01), as well as significantly positive correlation of visfatin in blood serum and SBP level (r=0.331; p ˂0.05). A positive relationship was established between adiponectin in serum and in lymphocytes and INR (r=0.303; p ˂0.05) and an inverse relationship between serum irisin indicators and the prothrombin index (r=-0.359; p ˂0.05). Conclusion. In patients who achieved the target BP range on the background of low concentrations of total cholesterol and LDL cholesterol, serum visfatin, the content of adiponectin was significantly higher compared with patients of group II, in whom higher BP was worse controlled by antihypertensive drugs. Accordingly, patients who did not reach the target BP range had significantly higher levels of visfatin against a background of significantly lower levels of adiponectin and irisin.
- 30 September 2024
- Published by Bogomolets National Medical University in Medical Science of Ukraine (MSU)
- Vol. 20 (3) , 24-33
Open AccessTHE ROLE OF ADIPONECTIN, VISFATIN AND IRISIN IN THE PATHOGENESIS AND TREATMENT OF ARTERIAL HYPERTENSION
Background. The pathogenesis of arterial hypertension is not fully understood, although the main mechanisms of blood pressure regulation are generally outlined. An important role in the pathogenesis of hypertension, in addition to the well-known factors, is played by excessive expression of pro-inflammatory cytokines, which are produced by adipose tissue. Aim: to determine the role of adiponectin, visfatin and irisin in the pathogenesis and treatment of arterial hypertension. Materials and methods. 70 patients with arterial hypertension were examined in a randomized manner. Patients were divided into two groups: group 1 - 33 patients with controlled blood pressure and group 2 - 37 people with elevated blood pressure. All study participants underwent a thorough collection of disease and life anamnesis, a general physical examination with measurement of blood pressure (BP), anthropometric measurements with calculation of body mass index (BMI), complete blood count, coagulation test, blood chemistry test, as well as, enzyme-linked immunosorbent assay to determine the level of adiponectin, visfatin, irisin in blood serum and lymphocytes. An echocardiographic examination (EchoCG) was additionally performed. Results. Patients of the first group with normal blood pressure had significantly higher levels of adiponectin (p ˂ 0.01) and irisin (p ˂ 0.05) in blood serum, as well as significantly lower levels of visfatin in blood serum (p ˂ 0.05) compared to the patients of the second group. On the other hand, in lymphocytes, no significant difference was found between the indicators of adiponectin and visfatin between patients of the first and second groups. A positive correlation was found between the level of visfatin in lymphocytes and age (r=0.308; p ˂0.05), fibrinogen (r=0.472; p ˂0.01) and INR (r=0.551; p ˂0.01), as well as significantly positive correlation of visfatin in blood serum and SBP level (r=0.331; p ˂0.05). A positive relationship was established between adiponectin in serum and in lymphocytes and INR (r=0.303; p ˂0.05) and an inverse relationship between serum irisin indicators and the prothrombin index (r=-0.359; p ˂0.05). Conclusion. In patients who achieved the target BP range on the background of low concentrations of total cholesterol and LDL cholesterol, serum visfatin, the content of adiponectin was significantly higher compared with patients of group II, in whom higher BP was worse controlled by antihypertensive drugs. Accordingly, patients who did not reach the target BP range had significantly higher levels of visfatin against a background of significantly lower levels of adiponectin and irisin.
- 1 December 2023
- Published by Bentham Science Publishers Ltd. in Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
- Vol. 22 (4) , 250-260
Galectin-3 in Blood Serum and Lymphocytes as a Marker of Myocardial Damage in Patients with Arterial Hypertension and COVID-19
Background:: The constant increase of arterial hypertension and the development of pathology at an earlier age are global healthcare problems that cause damage to vital organs and worsen patient prognosis. In recent years, studies have shown that galectin-3 plays a role in the development and progression of arterial hypertension and coronavirus disease (COVID-19). Objective:: The explanatory research study aimed to analyze the prognostic value of galectin-3 de-termination in the serum blood and lymphocytes of patients with arterial hypertension and corona-virus disease (COVID-19). Methods:: The patients were divided into two groups: Group 1 consisted of 36 individuals with AH, Group 2 included 35 patients with arterial hypertension and polysegmental COVID-19 pneumonia, and 16 practically healthy individuals were included in the control group. All patients underwent anthropometry, biochemical blood analysis, determination of galectin-3, level in serum and lym-phocytes, IL-1β, IL-6, and echocardiography. Results:: The highest level of galectin-3 was found in patients of Group 1, while in patients of Group 2, the concentration of galectin-3 was significantly decreased, mostly due to the treatment of COVID-19, in addition to prolonged antihypertensive therapy. Conclusion:: The level of galectin-3 in serum and lymphocytes was significantly higher in patients of both groups compared to the control group (p<0.05). Arterial hypertension causes structural changes in the cardiovascular system that are associated with elevated levels of galectin-3 in serum and lymphocytes. It can be used as a marker of myocardial damage in the context of arterial hyper-tension and COVID-19.
- 1 December 2023
- Published by Bentham Science Publishers Ltd. in Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
- Vol. 22 (4) , 250-260
Galectin-3 in Blood Serum and Lymphocytes as a Marker of Myocardial Damage in Patients with Arterial Hypertension and COVID-19
Background:: The constant increase of arterial hypertension and the development of pathology at an earlier age are global healthcare problems that cause damage to vital organs and worsen patient prognosis. In recent years, studies have shown that galectin-3 plays a role in the development and progression of arterial hypertension and coronavirus disease (COVID-19). Objective:: The explanatory research study aimed to analyze the prognostic value of galectin-3 de-termination in the serum blood and lymphocytes of patients with arterial hypertension and corona-virus disease (COVID-19). Methods:: The patients were divided into two groups: Group 1 consisted of 36 individuals with AH, Group 2 included 35 patients with arterial hypertension and polysegmental COVID-19 pneumonia, and 16 practically healthy individuals were included in the control group. All patients underwent anthropometry, biochemical blood analysis, determination of galectin-3, level in serum and lym-phocytes, IL-1β, IL-6, and echocardiography. Results:: The highest level of galectin-3 was found in patients of Group 1, while in patients of Group 2, the concentration of galectin-3 was significantly decreased, mostly due to the treatment of COVID-19, in addition to prolonged antihypertensive therapy. Conclusion:: The level of galectin-3 in serum and lymphocytes was significantly higher in patients of both groups compared to the control group (p<0.05). Arterial hypertension causes structural changes in the cardiovascular system that are associated with elevated levels of galectin-3 in serum and lymphocytes. It can be used as a marker of myocardial damage in the context of arterial hyper-tension and COVID-19.
- Open Access
- 30 September 2023
- Published by Bogomolets National Medical University in Medical Science of Ukraine (MSU)
- Vol. 19 (3) , 23-30
THE RELATIONSHIP BETWEEN INSULIN RESISTANCE, ADIPOKINES, LIPIDS AND LOW-GRADE INFLAMMATION IN PATIENTS WITH CARDIOVASCULAR DISEASE TREATED BY STATINS
Background. Hypolipidemic and hypotensive therapy enables to improve prognosis and decrease the risk of cardiovascular pathologies, however, an intensive regimen of prescribing statins for patients with arterial hypertension (AH) combined with obesity can promote development of hyperinsulinemia and insulin resistance (IR), which are predictors of type 2 diabetes mellitus development. Aim: To investigate the relationship between insulin resistance, adipokines, lipids and low-grade inflammation in patients with cardiovascular disease treated by statins. Materials and methods: 81 patients with overweight and/or obesity and AH or combination of AH and CAD were involved. Patients’ age ranged from 35 to 79 years, among them there were 51 males and 30 females. ACE inhibitors and ARBs, diuretics were used for treatment of AH; atorvastatin was prescribed orally in the dose 20 mg or 40 mg per day permanently as hypolipidemic therapy. Lipid spectrum, biochemical indices and glycated hemoglobin were determined according to common techniques on an analyzer “BioSystems” (Spain) using original kits of reagents. Concentration of insulin and hsCRP were determined on immunochemoluminescent analyzer “Immulite 2000” (Siemens, Germany). Insulin resistance index was calculated by the formula: НОМA-IR=fasting insulin (mcIU/ml)*fasting glucose(mmol/L)/22.5 In НОМA-IR value > 2.77, patients were considered insulin resistant. Leptin was measured using an ELISA kit DRG (USA). Adiponectin was quantified using the ELISA kit Mediagnost (Germany). Results. It has been revealed in our investigation that body mass index, the level of systolic blood pressure, triglycerides, highly sensitive C-reactive protein and leptin were reliably higher in patients with IR, whereas adiponectin level was lower. These associations are confirmed by the results of studying correlations between IR index, adipokines, anthropometric and biochemical parameters. Thus, thorough evaluation of carbohydrate and adipokine profile in patients with cardiovascular pathology combined with obesity, who are subjected to hypolipidemic therapy, is an important factor in preventing type 2 diabetes mellitus. Conclusion. Assessment of the risk of statin-induced diabetes mellitus is important for determining intensity of statin therapy, namely, presence of insulin resistance, levels of hsCRP and adipokines should be considered at the beginning and during treatment. Актуальність. Гіполіпідемічна та гіпотензивна терапія дозволяє покращити прогноз та знизити ризик розвитку серцево-судинної патології, однак інтенсивний режим призначення статинів хворим на артеріальну гіпертензію (АГ) у поєднанні з ожирінням може сприяти розвитку гіперінсулінемії та інсулінорезистентності (ІР), що є предикторами виникнення цукрового діабету 2 типу. Ціль: дослідити зв’язок між інсулінорезистентністю, адипокінами, ліпідами та низькорівневим запаленням у пацієнтів із серцево-судинними захворюваннями, які лікуються статинами. Матеріали і методи. Залучено 81 пацієнта з надлишковою масою тіла та/або ожирінням та АГ або поєднанням АГ та ІХС. Вік хворих від 35 до 79 років, серед них 51 чоловік і 30 жінок. Для лікування АГ використовували інгібітори АПФ та БРА, діуретики; аторвастатин призначали перорально в дозі 20 мг або 40 мг на добу постійно. Ліпідний спектр, біохімічні показники та глікований гемоглобін визначали за загальноприйнятими методиками на аналізаторі “BioSystems” (Іспанія) з використанням оригінальних наборів реактивів. Концентрацію інсуліну та високочутливого С-реактивного протеїну (вчСРП) визначали на імунохемолюмінесцентному аналізаторі «Immulite 2000» (Siemens, Німеччина). Індекс інсулінорезистентності розраховували за формулою: НОМА-IR =інсулін натще (мкМО/мл)*глюкоза натще (ммоль/л)/22,5 При значенні НОМА-IR > 2,77 пацієнти вважалися інсулінорезистентними. Лептин вимірювали за допомогою набору ELISA DRG (США). Кількісне визначення адипонектину проводили за допомогою набору ELISA Mediagnost (Німеччина). Результати. У нашому дослідженні було виявлено, що індекс маси тіла, рівень систолічного артеріального тиску, тригліцеридів, вчСРП та лептину були достовірно вищими у пацієнтів з ІР, тоді як рівень адипонектину був нижчим. Це підтверджується результатами вивчення кореляційних зв’язків між НОМА-IR, адипокінами, антропометричними та біохімічними параметрами. Таким чином, ретельна оцінка...
- 30 September 2023
- Published by Bogomolets National Medical University in Medical Science of Ukraine (MSU)
- Vol. 19 (3) , 23-30
Open AccessTHE RELATIONSHIP BETWEEN INSULIN RESISTANCE, ADIPOKINES, LIPIDS AND LOW-GRADE INFLAMMATION IN PATIENTS WITH CARDIOVASCULAR DISEASE TREATED BY STATINS
Background. Hypolipidemic and hypotensive therapy enables to improve prognosis and decrease the risk of cardiovascular pathologies, however, an intensive regimen of prescribing statins for patients with arterial hypertension (AH) combined with obesity can promote development of hyperinsulinemia and insulin resistance (IR), which are predictors of type 2 diabetes mellitus development. Aim: To investigate the relationship between insulin resistance, adipokines, lipids and low-grade inflammation in patients with cardiovascular disease treated by statins. Materials and methods: 81 patients with overweight and/or obesity and AH or combination of AH and CAD were involved. Patients’ age ranged from 35 to 79 years, among them there were 51 males and 30 females. ACE inhibitors and ARBs, diuretics were used for treatment of AH; atorvastatin was prescribed orally in the dose 20 mg or 40 mg per day permanently as hypolipidemic therapy. Lipid spectrum, biochemical indices and glycated hemoglobin were determined according to common techniques on an analyzer “BioSystems” (Spain) using original kits of reagents. Concentration of insulin and hsCRP were determined on immunochemoluminescent analyzer “Immulite 2000” (Siemens, Germany). Insulin resistance index was calculated by the formula: НОМA-IR=fasting insulin (mcIU/ml)*fasting glucose(mmol/L)/22.5 In НОМA-IR value > 2.77, patients were considered insulin resistant. Leptin was measured using an ELISA kit DRG (USA). Adiponectin was quantified using the ELISA kit Mediagnost (Germany). Results. It has been revealed in our investigation that body mass index, the level of systolic blood pressure, triglycerides, highly sensitive C-reactive protein and leptin were reliably higher in patients with IR, whereas adiponectin level was lower. These associations are confirmed by the results of studying correlations between IR index, adipokines, anthropometric and biochemical parameters. Thus, thorough evaluation of carbohydrate and adipokine profile in patients with cardiovascular pathology combined with obesity, who are subjected to hypolipidemic therapy, is an important factor in preventing type 2 diabetes mellitus. Conclusion. Assessment of the risk of statin-induced diabetes mellitus is important for determining intensity of statin therapy, namely, presence of insulin resistance, levels of hsCRP and adipokines should be considered at the beginning and during treatment. Актуальність. Гіполіпідемічна та гіпотензивна терапія дозволяє покращити прогноз та знизити ризик розвитку серцево-судинної патології, однак інтенсивний режим призначення статинів хворим на артеріальну гіпертензію (АГ) у поєднанні з ожирінням може сприяти розвитку гіперінсулінемії та інсулінорезистентності (ІР), що є предикторами виникнення цукрового діабету 2 типу. Ціль: дослідити зв’язок між інсулінорезистентністю, адипокінами, ліпідами та низькорівневим запаленням у пацієнтів із серцево-судинними захворюваннями, які лікуються статинами. Матеріали і методи. Залучено 81 пацієнта з надлишковою масою тіла та/або ожирінням та АГ або поєднанням АГ та ІХС. Вік хворих від 35 до 79 років, серед них 51 чоловік і 30 жінок. Для лікування АГ використовували інгібітори АПФ та БРА, діуретики; аторвастатин призначали перорально в дозі 20 мг або 40 мг на добу постійно. Ліпідний спектр, біохімічні показники та глікований гемоглобін визначали за загальноприйнятими методиками на аналізаторі “BioSystems” (Іспанія) з використанням оригінальних наборів реактивів. Концентрацію інсуліну та високочутливого С-реактивного протеїну (вчСРП) визначали на імунохемолюмінесцентному аналізаторі «Immulite 2000» (Siemens, Німеччина). Індекс інсулінорезистентності розраховували за формулою: НОМА-IR =інсулін натще (мкМО/мл)*глюкоза натще (ммоль/л)/22,5 При значенні НОМА-IR > 2,77 пацієнти вважалися інсулінорезистентними. Лептин вимірювали за допомогою набору ELISA DRG (США). Кількісне визначення адипонектину проводили за допомогою набору ELISA Mediagnost (Німеччина). Результати. У нашому дослідженні було виявлено, що індекс маси тіла, рівень систолічного артеріального тиску, тригліцеридів, вчСРП та лептину були достовірно вищими у пацієнтів з ІР, тоді як рівень адипонектину був нижчим. Це підтверджується результатами вивчення кореляційних зв’язків між НОМА-IR, адипокінами, антропометричними та біохімічними параметрами. Таким чином, ретельна оцінка...
- Open Access
- 30 March 2022
- Published by Bogomolets National Medical University in Medical Science of Ukraine (MSU)
- Vol. 18 (1) , 3-7
THE LEVEL OF LEUKOTRIENE B4 IN PATIENTS WITH ARTERIAL HYPERTENSION AND CORONAVIRUS DISEASE
Relevance. Patients with comorbid pathology, including arterial hypertension (AH), coronary artery disease, type 2 diabetes, and cerebrovascular disease have been shown to be at risk for coronavirus disease (COVID-19). Currently, among the pathogenetic mechanisms of vascular endothelial damage are considered direct effects of SARS-COV-2 virus, as well as proinflammatory cytokines, which lead to a «cytokine storm» with unpredictable consequences for the patient. In this aspect, the role of leukotriene B4 (LTB4) – one of the first candidates to provoke a hyperimmune inflammatory response in the progression of COVID-19 – was insufficiently elucidated. Objective: to investigate the level of leukotriene B4 (LTB4) in patients with AH with and without coronavirus disease 2019. Methods. 78 people with AH and overweight or obesity who were treated at the Lviv Emergency Hospital were examined. All patients were divided into 2 groups: group 1 (n=37) – persons with AH (stage І-ІІІ, grade 1-3); group 2 (n=41) – patients with AH (stage І-ІІІ, grade 1-3), COVID -19 and interstitial lung disease. Anthropometric measurements with a determination of body mass index (BMI), echocardiography, a blood test, biochemical blood test with determination of glucose, alanine aminotransferase, aspartate aminotransferase, creatinine, and urea were performed. Serum blood samples for the examination of LTB4 (Elabscience Elisa Kit) were taken and processed using ELISA method. Results. Saturation was significantly lower in patients of group 2, while heart rate and body temperature were higher (p < 0,01) compared to group 1. There was a significant decrease in hemoglobin level, increase in ESR, glucose, and LTB4 in individuals with AH and COVID-19, which is probably due to the presence of inflammation in the lung tissue in coronavirus infection. The concentration of LTB4 ranged from 370 to 3600 pg/l in patients of group 2. 19 individuals (46,3%) of group 2 had a higher level of LTB4 than the median value, which is probably associated with a more severe course of coronavirus infection. A positive correlation between LTB4 and BMI (rs= 0,369; p < 0,05) was found in individuals with AH. Conclusions. The level of LTB4 is higher in patients with AH and COVID – 19 than in individuals with AH, due to the severity of the inflammation process in this comorbid pathology.
- 30 March 2022
- Published by Bogomolets National Medical University in Medical Science of Ukraine (MSU)
- Vol. 18 (1) , 3-7
Open AccessTHE LEVEL OF LEUKOTRIENE B4 IN PATIENTS WITH ARTERIAL HYPERTENSION AND CORONAVIRUS DISEASE
Relevance. Patients with comorbid pathology, including arterial hypertension (AH), coronary artery disease, type 2 diabetes, and cerebrovascular disease have been shown to be at risk for coronavirus disease (COVID-19). Currently, among the pathogenetic mechanisms of vascular endothelial damage are considered direct effects of SARS-COV-2 virus, as well as proinflammatory cytokines, which lead to a «cytokine storm» with unpredictable consequences for the patient. In this aspect, the role of leukotriene B4 (LTB4) – one of the first candidates to provoke a hyperimmune inflammatory response in the progression of COVID-19 – was insufficiently elucidated. Objective: to investigate the level of leukotriene B4 (LTB4) in patients with AH with and without coronavirus disease 2019. Methods. 78 people with AH and overweight or obesity who were treated at the Lviv Emergency Hospital were examined. All patients were divided into 2 groups: group 1 (n=37) – persons with AH (stage І-ІІІ, grade 1-3); group 2 (n=41) – patients with AH (stage І-ІІІ, grade 1-3), COVID -19 and interstitial lung disease. Anthropometric measurements with a determination of body mass index (BMI), echocardiography, a blood test, biochemical blood test with determination of glucose, alanine aminotransferase, aspartate aminotransferase, creatinine, and urea were performed. Serum blood samples for the examination of LTB4 (Elabscience Elisa Kit) were taken and processed using ELISA method. Results. Saturation was significantly lower in patients of group 2, while heart rate and body temperature were higher (p < 0,01) compared to group 1. There was a significant decrease in hemoglobin level, increase in ESR, glucose, and LTB4 in individuals with AH and COVID-19, which is probably due to the presence of inflammation in the lung tissue in coronavirus infection. The concentration of LTB4 ranged from 370 to 3600 pg/l in patients of group 2. 19 individuals (46,3%) of group 2 had a higher level of LTB4 than the median value, which is probably associated with a more severe course of coronavirus infection. A positive correlation between LTB4 and BMI (rs= 0,369; p < 0,05) was found in individuals with AH. Conclusions. The level of LTB4 is higher in patients with AH and COVID – 19 than in individuals with AH, due to the severity of the inflammation process in this comorbid pathology.